Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas A Moore

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2020
CSTI-300 (SMP-100); a Novel 5-HT<sub>3</sub> Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid SyndromeAlexander Roberts, Gillian Grafton, Andrew D Powell, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2005
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapineKurt Rasmussen, Mark J Benvenga, Frank P Bymaster, et al.
Journal of Medicinal Chemistry|August 26, 2016
Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1Christopher L Cioffi, Shuang Liu, Mark A Wolf, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
The Journal of Pharmacology and Experimental Therapeutics|February 28, 2020
CSTI-300 (SMP-100); a Novel 5-HT<sub>3</sub> Receptor Partial Agonist with Potential to Treat Patients with Irritable Bowel Syndrome or Carcinoid SyndromeAlexander Roberts, Gillian Grafton, Andrew D Powell, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 6, 2005
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapineKurt Rasmussen, Mark J Benvenga, Frank P Bymaster, et al.
Journal of Medicinal Chemistry|August 26, 2016
Synthesis and Biological Evaluation of N-((1-(4-(Sulfonyl)piperazin-1-yl)cycloalkyl)methyl)benzamide Inhibitors of Glycine Transporter-1Christopher L Cioffi, Shuang Liu, Mark A Wolf, et al.
Pageof 3